Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?

Area of Science:

• Cardiovascular Genetics
• Lipid Metabolism
• Hemostasis and Thrombosis

Background:

• Familial hypercholesterolemia (FH) is a prevalent autosomal dominant genetic disorder affecting lipid metabolism.
• Elevated low-density lipoprotein cholesterol (LDLc) in FH significantly increases cardiovascular risk.
• Understanding the interplay between lipid profiles, PCSK9, and hemostasis is crucial for effective FH management.

Purpose of the Study:

• To evaluate proprotein convertase subtilisin/kexin 9 (PCSK9) levels, lipid profiles, and thrombin generation in FH patients.
• To compare the efficacy of statin monotherapy versus combined statin and ezetimibe therapy in FH.
• To investigate the association between PCSK9, lipid parameters, and hemostatic function in FH.

Main Methods:

• Eighty FH patients were divided into two groups: statin monotherapy (n=53) and combined therapy (statin + ezetimibe) (n=27).
• Proprotein convertase subtilisin/kexin 9 (PCSK9) levels were measured using ELISA.
• Lipid profiles were assessed colorimetrically, and thrombin generation assay (TGA) was performed using the CAT method.

Main Results:

• Combined therapy significantly reduced total cholesterol (TC) and LDLc compared to statin monotherapy.
• Thrombin generation potential (ETP) was significantly lower in the conjugate therapy group.
• PCSK9 positively correlated with TC, LDLc, and triglycerides; TGA parameters correlated with PCSK9 and lipid profiles.

Conclusions:

• PCSK9 levels are linked to lipid and hemostatic profiles in FH patients, influenced by age.
• Combined therapy (statin + ezetimibe) demonstrates superior improvement in lipid and hemostatic profiles.
• Combined therapy offers reduced atherogenic and thrombogenic risks, presenting a more promising FH treatment than statin monotherapy.